By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indivumed and Apceth today announced a partnership to develop technology that can predict patient response to targeted cellular or gene therapies in different cancer types.

The technology, which would allow patients to be stratified based on their response to therapies, would use Indivumed's analytical platform for cancer tissue in order to identify and validate protein biomarkers and targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.